Results 181 to 190 of about 53,618 (254)
Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8277-8287, September 2026.ABSTRACT Aims Treatment options for metabolic dysfunction‐associated steatotic liver disease (MASLD) are limited. While glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) and sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors improve cardiovascular outcomes, comparative effectiveness on liver‐related outcomes remains unclear.
Gregor A. Maier +4 more
wiley +1 more source
Development and validation of the polycystic ovary syndrome-related complaint severity scale. [PDF]
Rev Assoc Med Bras (1992)Kaplan Ö +5 more
europepmc +1 more source
Prevalence of Obesity and Related Conditions and GLP‐1 Use in Medicare Fee‐for‐Service Beneficiaries
Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8398-8406, September 2026.ABSTRACT Aims This study estimated the number and percentage of Medicare fee‐for‐service (FFS) beneficiaries who use GLP‐1 RAs, are currently eligible or could become eligible if ongoing‐trial indications receive approval and coverage. Materials and Methods This retrospective cohort study used Medicare enrolment and claims data, representing 100% of ...
Sonia Kim +3 more
wiley +1 more source
Prevalence of polycystic ovary syndrome among adolescents depending on the adopted diagnostic criteria. [PDF]
Front Endocrinol (Lausanne)Jakubowska-Kowal K +3 more
europepmc +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8460-8468, September 2026.ABSTRACT Aims This study aimed to analyse incident glucose lowering drug (GLD) utilisation in Australia between the period 2014 and 2024. Materials and Methods Australian Pharmaceutical Benefits Scheme (PBS) data (10% PBS dataset) were analysed to assess the proportions of incident monotherapy, dual therapy and triple therapy and the proportion of ...
Peter S. Hamblin +5 more
wiley +1 more source
The pathogenesis, therapeutic targets and drugs of polycystic ovary syndrome. [PDF]
Front Endocrinol (Lausanne)Chen Y, Sun X, Xia X, Chen K, Zeng F.
europepmc +1 more source
The Role of Fat‐Free Mass in Weight‐Related Complications: A Rapid Review and Meta‐Analysis
Obesity Reviews, Volume 27, Issue 9, September 2026.ABSTRACT Background This review synthesized evidence on the association between fat‐free mass (FFM) metrics and weight‐related metabolic complications in adults with overweight or obesity. Methods A systematic search of Medline, Embase, Web of Science, and Google Scholar (inception to October 2024) identified 32 observational studies involving 138,935 ...
Tadesse Asmamaw Dejenie +4 more
wiley +1 more source
Outcome-specific shifts in homocysteine-androgen correlations in polycystic ovary syndrome. [PDF]
Front Endocrinol (Lausanne)Han Q, Zhao J, Li M, Xin M, Yin X, He J.
europepmc +1 more source
A Quarter Century of EHD Protein Research: From Endosomal Recycling to Ciliopathies
Traffic, Volume 27, Issue 3, September 2026.Human EHD protein subcellular localization. ABSTRACT Eps15 homology domain‐containing proteins comprise a conserved family of membrane‐remodeling ATPases that regulate endocytic trafficking, membrane fission, receptor recycling, primary ciliogenesis and membrane dynamics across eukaryotes. Since the initial identification of EHD1 and its Caenorhabditis
Devin Frisby +3 more
wiley +1 more source
New Challenges and Perspectives in Polycystic Ovary Syndrome. [PDF]
J Clin MedParker J, Hitch V.
europepmc +1 more source